Rossari Biotech Q2 FY27: PAT ₹350.95 Cr & Rev ₹7,003.87 Cr

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Investor Takeaways

Reported Q1 FY2026 revenue of ₹4,844.63 crores and profit after tax of ₹350.95 crores, up from ₹350.95 million last year, with EPS of 6.34.

Board approved unaudited financials, granted 4,000 stock options, and approved transfer of 100% of Rossari International to Singapore.

Proposed Rs. 24 crore sale of RILC shares to Singapore entity pending Saudi regulatory approval, targeting completion by March 31, 2027.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹4,844.63 Cr	↑ from ₹350.95 million ([amount not verified])
Net Profit	₹350.95 Cr	↑ from ₹350.95 million ([amount not verified])
EPS	₹6.34
OPM	Not available

What Changed

The filing confirms approval of unaudited Q1 FY2026 results showing revenue of ₹4,844.63 crores and profit after tax of ₹350.95 crores, up from ₹350.95 million in the prior year. The board granted 4,000 stock options and approved the transfer of 100% of Rossari International to Singapore. A proposed Rs. 24 crore sale of RILC shares to the Singapore entity is pending Saudi regulatory approval, with completion targeted by March 31, 2027. The company also disclosed current fundamentals including a market cap of ₹2,806 crores and P/E ratio of 20.58.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Rossari Biotech Limited	20.58	N/A	N/A	2,806
Solar Industries India Limited	132.27	N/A	N/A	1,56,674.48
Pidilite Industries Limited	75.73	N/A	N/A	1,49,378.89
SRF Limited	69.51	N/A	N/A	79,723.46

Rossari Biotech trades at a significantly lower P/E ratio compared to peers like Solar Industries (132.27) and Pidilite (75.73), suggesting potential relative valuation differences within the chemicals sector.

Risks & Concerns

No specific risks identified in this filing.

Pending Saudi regulatory approval for the Rs. 24 crore share sale to Singapore entity introduces execution risk.

Restructuring involving transfer of 100% of Rossari International to Singapore may involve operational or tax implications not detailed in this filing.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	512.73	31.7	12.63
Q2FY25	498.35	35.33	13.23
Q1FY25	489.65	34.9	13.25
Q4FY24	472.72	34.13	13.45

The reported Q1 FY2026 revenue of ₹4,844.63 crores and profit of ₹350.95 crores represent a significant increase compared to the previous year's ₹350.95 million, though the quarterly trend shows sequential revenue and profit growth from ₹472.72 crore (Q4FY24) to ₹4,844.63 crore (Q1 FY2026), indicating a material uplift in scale. OPM trends remain stable around 13% in prior quarters, though not provided for the latest period.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

Metric	Value
Revenue	₹7,003.87 Cr
Net Profit (PAT)	₹350.95 Cr

📢 Key Event
Board approves Q1 FY2026 results, ESOP grant, and subsidiary restructuring

🔮 What's Next
Transaction to be completed by March 31, 2027, subject to Saudi approvals

💡 Investor Takeaway
The company is restructuring its international operations while reporting lower quarterly profits and expanding employee stock options.

Rossari Biotech reported Q1 FY2026 unaudited financials showing revenue of [amount not verified], down 16.6% YoY, with profit before tax at [amount context mismatch] crores and profit after tax at [amount not verified]. The company approved 4,000 stock options under its 2019 ESOP and allotted 2,500 shares, increasing paid-up capital to [amount not verified]. It also proposed transferring 100% of Rossari International Limited to its Singapore subsidiary for Rs. 24 crores, subject to Saudi approvals. The transaction is arm's length and compliant with SEBI regulations. No material impact on financials is expected.

📊 Stock Analysis — ROSSARI ✨ Ask AI About This

About Rossari Biotech Limited (ROSSARI)

Chemicals · Chemicals · Listed on NSE

Market Cap: ₹2,644.67 Cr P/E: 17.5 ROE: 11.3% ROCE: 13.7% Div Yield: 0.10%

View full ROSSARI stock details →

📡 Get AI alerts when ROSSARI files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ROSSARI — Free

💡 Ask AI about this filing

"What is the valuation of RILC shares being sold?" "How will the Saudi approval impact the timeline?" "What is the expected impact on EPS after the restructuring?"

Ask AI Free →

📊 More ROSSARI filings

See all ROSSARI filings →

🔥 Also filed on 18 July 2026

SHREYANIND Shreyans Industries Limited Corporate Action CAMLINFINE Camlin Fine Sciences Limited Annual Report MAPMYINDIA C.E. Info Systems Limited Annual Report ICICIBANK ICICI Bank Limited Financial Results CAMLINFINE Camlin Fine Sciences Limited Annual Report AUTOAXLES Automotive Axles Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ROSSARI files new disclosures

Track ROSSARI filings, board meetings, and corporate actions. Free email alerts at 5 PM.